GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review - PubMed
3 hours ago
- #thromboembolic risk
- #GLP-1 receptor agonists
- #weight management
- GLP-1 receptor agonists (GLP-1RAs) like semaglutide and liraglutide lead to significant weight loss in high-risk populations (e.g., with cancer, diabetes, cardiovascular disease).
- These drugs reduce major cardiovascular events, with hazard ratios as low as 0.74, indicating cardiovascular benefits.
- Direct evidence on venous thromboembolism risk reduction is limited, but some data suggest potential benefits, though not statistically significant in one study.
- Safety profiles are acceptable, with slight increases in gallbladder events but no consistent cancer risk, and serious adverse events are similar or lower compared to controls.
- Further large-scale studies are needed to confirm the role of GLP-1RAs in reducing thromboembolic risk.